Articles producció científica> Medicina i Cirurgia

Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy

  • Identification data

    Identifier: imarina:9243594
    Authors:
    Domingo PMateo MGVillarroya JCereijo RTorres FDomingo JCCampderrós LGallego-Escuredo JMGutierrez MDMMur ICorbacho NVidal FVillarroya FGiralt M
    Abstract:
    Objective: People living with HIV (PLWH) have an increased cardiovascular risk (CVR) owing to dyslipidemia, insulin resistance, metabolic syndrome, and HIV/combination antiretroviral therapy (cART)-associated lipodystrophy (HALS). Atherosclerosis and inflammation are related to growth differentiation factor-15 (GDF15). The relationship between metabolic disturbances, HALS, and CVR with GDF15 in PLWH is not known. Research design and methods: Circulating GDF15 levels in 152 PLWH (with HALS = 60, without HALS = 43, cART-naïve = 49) and 34 healthy controls were assessed in a cross-sectional study. Correlations with lipids, glucose homeostasis, fat distribution, and CVR were explored. Results: PLWH had increased circulating GDF15 levels relative to controls. The increase was the largest in cART-treated PLWH. Age, homeostatic model assessment of insulin resistance 1 (HOMA1-IR), HALS, dyslipidemia, C-reactive protein, and CVR estimated with the Framingham score correlated with GDF15 levels. The GDF15-Framingham correlation was lost after age adjustment. No correlation was found between GDF15 and the D:A:D Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) score estimated CVR. CVR independent predictors were patient group (naïve, HALS−, and HALS+) and cumulated protease inhibitor or nucleoside reverse transcriptase inhibitor exposure. Conclusions: PLWH, especially when cART-treated, has increased GDF15 levels—this increase is associated with dyslipidemia, insulin resistance, metabolic syndrome, HALS, and inflammation-related parameters. GDF15 is unassociated with CVR when age-adjusted.
  • Others:

    Author, as appears in the article.: Domingo P; Mateo MG; Villarroya J; Cereijo R; Torres F; Domingo JC; Campderrós L; Gallego-Escuredo JM; Gutierrez MDM; Mur I; Corbacho N; Vidal F; Villarroya F; Giralt M
    Department: Medicina i Cirurgia
    URV's Author/s: Vidal Marsal, Francisco
    Keywords: Metabolic syndrome Insulin resistance Hals Gdf15 Framingham D:a:d Cardiovascular-disease Cardiovascular risk stress risk prediction profile metabolic syndrome marker lipodystrophy insulin resistance infection hals framingham events dysfunction d cardiovascular risk abacavir a
    Abstract: Objective: People living with HIV (PLWH) have an increased cardiovascular risk (CVR) owing to dyslipidemia, insulin resistance, metabolic syndrome, and HIV/combination antiretroviral therapy (cART)-associated lipodystrophy (HALS). Atherosclerosis and inflammation are related to growth differentiation factor-15 (GDF15). The relationship between metabolic disturbances, HALS, and CVR with GDF15 in PLWH is not known. Research design and methods: Circulating GDF15 levels in 152 PLWH (with HALS = 60, without HALS = 43, cART-naïve = 49) and 34 healthy controls were assessed in a cross-sectional study. Correlations with lipids, glucose homeostasis, fat distribution, and CVR were explored. Results: PLWH had increased circulating GDF15 levels relative to controls. The increase was the largest in cART-treated PLWH. Age, homeostatic model assessment of insulin resistance 1 (HOMA1-IR), HALS, dyslipidemia, C-reactive protein, and CVR estimated with the Framingham score correlated with GDF15 levels. The GDF15-Framingham correlation was lost after age adjustment. No correlation was found between GDF15 and the D:A:D Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) score estimated CVR. CVR independent predictors were patient group (naïve, HALS−, and HALS+) and cumulated protease inhibitor or nucleoside reverse transcriptase inhibitor exposure. Conclusions: PLWH, especially when cART-treated, has increased GDF15 levels—this increase is associated with dyslipidemia, insulin resistance, metabolic syndrome, HALS, and inflammation-related parameters. GDF15 is unassociated with CVR when age-adjusted.
    Thematic Areas: Medicine, general & internal Medicine (miscellaneous) Medicine (all)
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: francesc.vidal@urv.cat
    Author identifier: 0000-0002-6692-6186
    Record's date: 2024-09-07
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.mdpi.com/2077-0383/11/3/549
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Journal Of Clinical Medicine. 11 (3):
    APA: Domingo P; Mateo MG; Villarroya J; Cereijo R; Torres F; Domingo JC; Campderrós L; Gallego-Escuredo JM; Gutierrez MDM; Mur I; Corbacho N; Vidal F; Vill (2022). Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy. Journal Of Clinical Medicine, 11(3), -. DOI: 10.3390/jcm11030549
    Article's DOI: 10.3390/jcm11030549
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2022
    Publication Type: Journal Publications
  • Keywords:

    Medicine (Miscellaneous),Medicine, General & Internal
    Metabolic syndrome
    Insulin resistance
    Hals
    Gdf15
    Framingham
    D:a:d
    Cardiovascular-disease
    Cardiovascular risk
    stress
    risk prediction
    profile
    metabolic syndrome
    marker
    lipodystrophy
    insulin resistance
    infection
    hals
    framingham
    events
    dysfunction
    d
    cardiovascular risk
    abacavir
    a
    Medicine, general & internal
    Medicine (miscellaneous)
    Medicine (all)
  • Documents:

  • Cerca a google

    Search to google scholar